US
AU
UK
KR
FR
DE
CA
JP
SE
NL
ES
NO
IT
BENL
FI
HR
CHDE
CHFR
DK
About SomnoMed
Founded in 2004, SomnoMed is an Australian Stock Exchange listed medical device company operating in 28 countries.
With headquarters in Sydney, Australia and offices in Europe and the United States, SomnoMed focuses on developing and manufacturing clinically proven medical devices for the treatment of Obstructive Sleep Apnea (OSA). Patients around the world with mild and moderate OSA have been successfully treated with our oral appliances.
SomnoMed leads the world in the development of OSA devices with each appliance custom made using state-of-the-art technology delivering precision, comfort, and first-time fit solutions. SomnoMed’s continuous improvement has ensured oral sleep medicine devices have greater efficacy and are more comfortable than ever. Our devices are 510(k) cleared by the FDA (Food and Drug Administration) and manufactured in accordance with ISO 13485 quality standards.
At SomnoMed, we are committed to providing comfortable and effective OSA treatment that is effective and clinically proven to treat Obstructive Sleep Apnea (OSA). Our passion is to help patients regain their lives again by having a comfortable night sleep.
Our Mission
To delight our customers and patients with the highest quality products and services for the treatment of Obstructive Sleep Apnea (OSA).
Our history
2005
The SomnoDent® Classic, the first dorsal fin oral device for the treatment of OSA is launched.
2006
SomnoMed begins offering SomnoDent oral devices in North America.
2008
SomnoMed introduces b-flex Comfort Liner technology to the SomnoDent Classic, creating the SomnoDent Flex. The b-flex Comfort Liner® provides comfort and retention over other designs that use ball clasps. SomnoDent Flex goes on to be SomnoMed’s largest selling brand.
2013
For the Medicaid/ Medicare market in the USA, SomnoDent launches the Herbst oral sleep apnea device.
2014
SomnoDent Fusion® is launched, building on the success of SMH Bflex and the SomnoDent Flex. In addition to these features, the SomnoDent Fusion provides 3 removable wings to increase protrusion and efficacy.
2014
The SomnoDent Herbst Advance® is launched and becomes the first intraoral device featuring a visual calibration indicator to determine how far the device is protruded.
2015
The Dentitrac Compliance Recorders are added to SomnoMed oral devices to provide an objective measure of compliance for each patient.
2016
SomnoMed introduces the Morning Repositioner, a bite deprogrammer designed to help return the patient’s mandible in its normal position after a night’s sleep.
2017
The SomGauge, SomnoMed’s autoclavable bite registration instrument is launched, allowing dental professionals to easily produce more accurate and reliable bite records.
2019
The Herbst Advance® design is improved to add a patented anti-wind-back mechanism to maintain protrusion & strengthened with wire loops. There are no returns in the next 5000 devices manufactured.
2019
SomnoDent Avant®, our most comfortable and smallest profile device is launched in the USA and APAC. SomnoDen Avant uses an innovative strap that creates lip seal and encourages nasal breathing, reducing snoring and dry mouth. SomnoDent Avant uses a digital design and manufacturing platform and quickly becomes the fastest growing oral appliance in the industry.
2020
The SomnoDent Herbst Advance Elite® is launched in the US, the 2nd device manufactured using our digital platform, providing dentists with a device that has 18% greater flexural strength and a 3 year, no questions asked, product replacement plan.
Investors & partners
Our goal is to build the best in class oral sleep apnea device company. Our partners and investors trust in our company’s continuous growth and innovation. Find out more about investing or if you are a current investor get the latest information on SomnoMed’s developments.
